University of Pennsylvania
Philadelphia, United States
Publications on this disease79
Research view
Switch to patient viewGroups that published on this disease or run trials on it, from public registries and publications. Researchers appear by name only once their profile is published.
One card per institution. Pick a target or a country to narrow the list.
Philadelphia, United States
Publications on this disease79
1 of 1+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.
Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.
FDA · U01
NIH NIA · R01
NIH NINDS · R43
Development of an Anti-Nerve Growth Factor Active Immunotherapy for Difficult-to-Manage Pain
NIH NIAMS · R21
Failure to resolve an adaptive stress state contributes to Duchenne Muscular Dystrophy Severity
NIH NCI · R43
Preclinical development of novel dual EZH2-BRD4 inhibitor for EZH2-mutant lymphoma
European Commission (Horizon Europe) · HORIZON-ERC
Primary bone cancer scaffolds as controlled release non-viral gene delivery platforms (PANACEA)
European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF
The disease is named only in the funder's project summary, not in the title.
European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF
The disease is named only in the funder's project summary, not in the title.
European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF
Predicting single-cell ploidy from digital pathology images in pan-sarcoma (SImPloidy)
The disease is named only in the funder's project summary, not in the title.
European Commission (Horizon Europe) · HORIZON-IA
The disease is named only in the funder's project summary, not in the title.
10 of 473 running projects, newest first. Listed amounts together: US$249.7m + €53.4m.
Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.
Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.
Terminated
“\< 75 % participation”Registry text, quoted unchanged. SourceSuspended
“Other - Extend the observation period for current patients”Registry text, quoted unchanged. SourceTerminated
Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors
“Study terminated by sponsor”Registry text, quoted unchanged. SourceTrials whose registry record says individual participant data (IPD) will be shared.
Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.
See which targets of this disease your abstract mentions, and go to the people working on them.
Matched in your browser only. The text is not sent, saved or logged.
Sources: ClinicalTrials.gov, EU CTR, OpenAlex, PubMed, NIH RePORTER, CORDIS. Machine-matched links are labelled.